102 related articles for article (PubMed ID: 19237831)
1. [Biomarkers for colorectal cancer treatment].
Suk KT; Kim HS
Korean J Gastroenterol; 2009 Feb; 53(2):68-75. PubMed ID: 19237831
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of cancer: new roles for pathologists in colorectal cancer.
Hamilton SR
Mod Pathol; 2008 May; 21 Suppl 2():S23-30. PubMed ID: 18437170
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in Colorectal Cancer.
Yiu AJ; Yiu CY
Anticancer Res; 2016 Mar; 36(3):1093-102. PubMed ID: 26977004
[TBL] [Abstract][Full Text] [Related]
4. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Shimamoto Y; Nukatsuka M; Takechi T; Fukushima M
Int J Mol Med; 2016 Feb; 37(2):319-28. PubMed ID: 26676887
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
Kubo A; Hashimoto H; Takahashi N; Yamada Y
World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.
Schwarzenbach H; Goekkurt E; Pantel K; Aust DE; Stoehlmacher J
Int J Cancer; 2010 Aug; 127(4):881-8. PubMed ID: 19998340
[TBL] [Abstract][Full Text] [Related]
8. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers predictive of chemotherapy response in colorectal cancer.
Shiovitz S; Grady WM
Curr Gastroenterol Rep; 2015 Feb; 17(2):431. PubMed ID: 25663616
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers in colorectal carcinoma.
Puerta-García E; Cañadas-Garre M; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(10):1189-222. PubMed ID: 26237292
[TBL] [Abstract][Full Text] [Related]
11. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
13. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
Gajjar KK; Vora HH; Kobawala TP; Trivedi TI; Ghosh NR
Int J Biol Markers; 2018 May; 33(2):180-188. PubMed ID: 29799355
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
16. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
18. Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Yu J; Miller R; Zhang W; Sharma M; Holtschlag V; Watson MA; McLeod HL
Pharmacogenomics; 2008 Oct; 9(10):1459-66. PubMed ID: 18855534
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies for colorectal cancer.
Kerr DJ; Ferry DR
Hosp Med; 1998 Aug; 59(8):617-21. PubMed ID: 9829054
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
